7 Best Peptides for Burnout

What to Know Before Choosing a Peptide for Burnout

Burnout is not a single complaint. For some people it shows up mainly as a cognitive problem: the inability to concentrate, the fog that does not lift no matter how much sleep they get. For others it is primarily physical, a bone-deep fatigue that rest does not touch. For others still it is emotional, a blunted affect, a flattened response to things that used to matter. Most people experience some combination of all three, which is why the peptide conversation around burnout is wider than almost any other goal. Different compounds target different pieces of a genuinely complex biological picture.

Every compound on this list earned its spot through one criterion: people use it for burnout recovery, or are actively discussing using it. That is the whole test. FDA approval is not the threshold, and evidence depth is not the threshold. Whether a compound is prescribed by a telemedicine clinic or sourced as a research chemical does not determine eligibility. What matters is whether people in the real world are actually reaching for it when their goal is recovering from burnout. FDA-approved, telemedicine-prescribed, and research-only compounds are all on the same footing here. The evidence behind each one is described honestly in its entry, and where the evidence is thin or entirely community-reported, that is stated plainly.

The numbers in front of the entries are a spine for the list, not a ranking. The order reflects how prominently each compound appears in research and in documented real-world use for burnout, not a verdict that compound one is better than compound seven for you. One more thing before the entries: no peptide is FDA-approved specifically for burnout. Burnout is not an FDA-recognized diagnosis with a designated peptide treatment. Every compound here is used off-label, through compounding, or as a research chemical, and human clinical trials specifically for burnout are essentially nonexistent across the board.

1. Semax: For Cognitive Clarity and Brain Fog

Semax is a synthetic heptapeptide developed in Russia, derived from a fragment of adrenocorticotropic hormone. It shows up at the top of virtually every burnout-focused peptide discussion because the cognitive dimension of burnout is often what people feel most acutely and want addressed first. The fog, the inability to hold focus, the sense that the brain is running through mud: these are Semax's primary target.

Semax works primarily by elevating brain-derived neurotrophic factor, commonly called BDNF. BDNF is a protein that supports the growth and maintenance of neurons and plays a central role in learning, memory, and neuroplasticity. Think of it as fertilizer for brain cells: when levels are low, the brain's capacity to adapt, repair, and function under stress is compromised. Semax pushes BDNF back up. It also appears to modulate dopamine pathways, which contributes to its reported effects on motivation and mental stamina under sustained stress loads.

The evidence base is real but limited in Western terms. Most human research comes from Russian clinical literature, where Semax has been studied for stroke recovery, cognitive decline, and anxiety-related conditions. That body of work is not widely replicated in Western peer-reviewed journals. For burnout specifically, no controlled human trial exists. What exists is user-reported experience, and it is extensive: across community forums, Semax paired with Selank is one of the most consistently mentioned combinations people reach for when burnout is primarily cognitive. Users report improved focus, faster mental recovery from stress, and a reduction in the mental sluggishness that characterizes burnout's cognitive phase. Semax is available as a nasal spray, which makes it accessible to people who prefer not to inject. It is classified as a research chemical in the United States, and the FDA has specifically flagged semax as a bulk drug substance presenting significant safety risks in compounding contexts.

2. Selank: For Stress Resilience and Anxiety-Driven Burnout

Selank is another Russian-developed heptapeptide, derived from a fragment of tuftsin, an immunomodulatory peptide the body produces naturally. Where Semax targets the cognitive side of burnout, Selank targets the emotional and physiological stress load. It is the compound people most often reach for when burnout presents primarily as chronic anxiety, emotional dysregulation, or an inability to tolerate stress without an outsized response.

The mechanism involves multiple pathways. Selank modulates dopamine and serotonin systems, the neurotransmitters most associated with mood regulation and stress tolerance. It also acts on GABA pathways, the brain's primary inhibitory signaling system, producing an anxiolytic effect without the sedation associated with benzodiazepines. Users consistently describe it as calming without dulling, which matters for people using it during working hours. There are also reports of normalization in cortisol rhythms, which is relevant because burnout is deeply connected to hypothalamic-pituitary-adrenal axis dysregulation. The HPA axis is the hormonal feedback loop that governs how the body responds to and recovers from stress, and chronic burnout bends it out of shape.

Like Semax, the human evidence for Selank comes largely from Russian clinical research and is not well-represented in the Western peer-reviewed literature. For burnout specifically, the evidence is community-reported rather than clinical. The combination of Semax and Selank is probably the most discussed two-compound approach for burnout, with users reporting that Semax handles focus while Selank handles the anxiety that underlies much of the cognitive dysfunction. Selank can be administered subcutaneously or intranasally. Its regulatory status in the US mirrors Semax: it is classified as a research chemical, and the FDA has flagged selank acetate specifically for immunogenicity and aggregation concerns in compounding contexts.

3. MOTS-c: For Cellular Energy and Mitochondrial Recovery

MOTS-c stands for Mitochondrial Open Reading Frame of the Twelve S rRNA Type-C. The name is technical, but the concept behind it is genuinely interesting. It is a peptide encoded not in the nuclear genome but in the mitochondrial genome itself, making it one of a small class of compounds called mitokines: signaling molecules the mitochondria produce to communicate with the rest of the cell and with other tissues.

Mitochondria are the organelles that produce ATP, the energy currency your cells run on. When chronic stress impairs their function, you get the kind of fatigue burnout is famous for: exhaustion not explained by poor sleep or low nutrition because it is happening at the cellular level. MOTS-c is sometimes described as an exercise-mimetic because its primary mechanism runs through the same pathway that exercise activates. It increases a molecule called AICAR, which activates AMPK, the cellular energy sensor that shifts cells from storage mode into burning mode. That activation triggers glucose uptake, fat oxidation, and mitochondrial biogenesis, meaning the actual creation of new mitochondria. The compound also acts as a retrograde signal from the mitochondria to the cell nucleus, where it helps regulate genes involved in handling oxidative stress. The practical upshot is improved cellular energy production and better resilience to ongoing stress load.

The honest state of the evidence is that most of what exists comes from animal studies and cell culture experiments. The mechanistic picture in preclinical research is compelling and is the subject of serious scientific interest, particularly in longevity and metabolic research. Peer-reviewed work supports the Folate-AICAR-AMPK mechanism with real data. Human clinical trials for MOTS-c are essentially absent as of 2026, and for burnout specifically, the evidence is a combination of extrapolation from the mechanistic animal literature and user-reported experience from biohacking communities, where people describe improved energy and better tolerance for physical and mental stress. MOTS-c is classified as a research chemical and is not FDA-approved.

4. NAD+: For Replenishing the Cellular Energy Deficit

NAD+, nicotinamide adenine dinucleotide, is technically a coenzyme rather than a peptide, but it appears consistently in burnout recovery discussions because it addresses one of the most direct biological mechanisms behind burnout fatigue: mitochondrial energy production. NAD+ is a critical cofactor in the electron transport chain, the process by which mitochondria generate ATP. Without adequate NAD+, that process slows, and the result is the pervasive, functional fatigue that characterizes burnout. Chronic stress depletes NAD+ levels, and those levels also decline naturally with age, which is part of why burnout tends to be harder to recover from as people get older.

The mechanism extends beyond raw energy production. NAD+ activates sirtuins, a family of proteins that regulate gene expression related to metabolism, inflammatory response, and stress adaptation. Think of sirtuins as the cellular maintenance crew: they keep the system running cleanly, and they need NAD+ to do it. NAD+ also supports PARP activity, which is involved in repairing the DNA damage that accumulates under chronic stress. The combination of energy restoration and cellular repair support is what distinguishes NAD+ as a meaningful entry in a burnout list rather than just a generic wellness compound.

The evidence base here is broader than most other compounds on this list, though it comes with an important qualifier: the research is not burnout-specific. Human studies on NAD+ precursors, primarily NMN and NR (nicotinamide riboside), exist in the context of aging and metabolic health, and that literature is more developed than anything in the peptide space. For burnout as a specific indication, no controlled human trial exists. IV NAD+ infusions are offered at wellness and compounding clinics and are generally well-tolerated, with flushing and nausea being the most common side effects during infusion. Oral NAD+ itself has poor bioavailability, so oral protocols typically use precursors NMN or NR instead. NAD+ and its precursors occupy a broader regulatory space than most compounds here, with oral forms available as dietary supplements.

5. BPC-157: For Root-Cause Inflammation and Gut-Brain Recovery

BPC-157 is a synthetic pentadecapeptide derived from a protein found in gastric juice. It is one of the most widely discussed peptides in general wellness and recovery communities, and it finds its way into burnout protocols primarily through two mechanisms: its effect on systemic and neuroinflammation, and its support for gut lining integrity.

The gut-brain connection matters for burnout because chronic stress damages the gut lining, increasing intestinal permeability and allowing inflammatory signals to enter the bloodstream and eventually cross into the central nervous system. BPC-157 promotes tissue repair through angiogenesis, the growth of new blood vessels to damaged areas, delivering the raw materials needed for repair. It also inhibits the NF-kB inflammatory signaling pathway. NF-kB is a master regulator of the inflammatory response; when it runs chronically elevated under ongoing stress, it contributes to the neuroinflammation that worsens cognitive symptoms and mood. Addressing that pathway while protecting gut integrity is the rationale for including BPC-157 in burnout stacks.

The human clinical evidence for BPC-157 in burnout is essentially nonexistent, and that needs to be said plainly. One retrospective case series of twelve patients with knee pain, not burnout, is the closest thing to a human clinical study, and it lacked controls. There are no randomized controlled trials for any indication in humans. The mechanistic and animal data is genuinely interesting, but the translation to human physiology for this specific use has not been established through clinical research. What exists for burnout is community-reported use, where BPC-157 appears frequently in recovery stacks alongside TB-500 and GHK-Cu. Users report improvements in recovery from physical stress and reductions in the somatic symptoms that often accompany burnout. The FDA has not approved BPC-157 for any indication and has issued warning letters to companies marketing it as a dietary supplement.

6. Sermorelin: For Growth Hormone Depletion from Chronic Stress

Sermorelin is a synthetic analog of growth hormone-releasing hormone, the natural signal the hypothalamus sends to trigger growth hormone production in the pituitary gland. Chronic stress depletes growth hormone, and that depletion contributes meaningfully to burnout: growth hormone plays a central role in cellular repair, metabolic regulation, and energy availability. Sermorelin does not replace growth hormone directly. It works by stimulating the pituitary to produce its own, preserving the natural feedback loop rather than overriding it. The analogy is turning up the volume on the original track rather than substituting a different recording.

What distinguishes Sermorelin from most other compounds on this list is its regulatory standing. It is among the few peptides with an FDA-approval history, approved for growth hormone deficiency in children. For adult burnout, its use is off-label, but it is available through licensed 503A and 503B compounding pharmacies and through telemedicine platforms. That clearer regulatory pathway, and the physician-supervised context in which it is typically used, distinguishes it from the research chemical end of this list. The evidence for burnout specifically is still off-label extrapolation rather than clinical trial data, but the underlying physiology is supported: depleted growth hormone is measurable in burnout states, and restoring it through a physiologically appropriate stimulus has a coherent rationale. People using Sermorelin for burnout-related fatigue and recovery capacity tend to do so in clinical settings, with reports describing gradual improvements in energy, sleep quality, and physical resilience over weeks of consistent use.

7. Thymosin Alpha-1: For Burnout Driven by Chronic Inflammation

Thymosin Alpha-1 is a naturally occurring peptide produced by the thymus gland, with a well-established role in immune regulation. It earns a place in the burnout conversation through a specific mechanism: the relationship between chronic inflammation and fatigue. Burnout is not always primarily a hormonal or cognitive problem. In some people, particularly those dealing with long-duration burnout or burnout layered onto a history of chronic illness, the dominant driver is an immune system that has been running in a low-grade inflammatory state for so long that it has begun to compromise cellular energy and mood function. Thymosin Alpha-1 modulates the immune response and reduces that chronic inflammatory burden.

The evidence situation for Thymosin Alpha-1 is worth understanding carefully. It has a genuinely robust human trial base, but that base applies to the wrong context. Published randomized controlled trials exist for its use in infectious disease and oncology, where its immune-modulating properties are well-characterized. For general wellness or burnout specifically, no human clinical trials exist. The evidence for burnout is extrapolated from the mechanism and from community-reported use. That extrapolation is more scientifically grounded than many community-use compounds because the underlying biology is established, but the gap between "proven to modulate immunity in serious illness" and "helpful for burnout-related inflammation" remains an extrapolation rather than a demonstrated finding.

Community discussions about Thymosin Alpha-1 for burnout tend to position it as an add-on for people whose burnout appears inflammation-driven: those with persistently elevated inflammatory markers, those who never fully recovered after illness, or those for whom cognitive and mood symptoms dominate without a clear hormonal explanation. It is classified as a research chemical in the US and is not FDA-approved for burnout or general wellness indications.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for burnout?

No peptide is FDA-approved specifically for burnout. Burnout is not an FDA-recognized diagnosis with a designated treatment, so every compound on this list is used off-label, through licensed compounding, or as a research chemical. Sermorelin has an FDA-approval history for growth hormone deficiency and is available through licensed compounding pharmacies, which gives it a clearer regulatory pathway than most others, but even that use for burnout is off-label extrapolation rather than an approved indication.

What is the difference between a compounded peptide and a research chemical?

A compounded peptide is prepared by a licensed 503A or 503B pharmacy under pharmacist supervision, typically prescribed by a physician, and subject to pharmaceutical-grade quality standards. A research chemical is sold outside the pharmaceutical chain, usually marketed for laboratory research rather than human use, without the same oversight of purity, sterility, or concentration. Several compounds on this list, including Semax and Selank, are available only through the research chemical channel in the US, and the FDA has specifically flagged both for safety concerns in compounding contexts. That sourcing difference carries real implications for quality and safety.

How long do people typically use these compounds before noticing a change?

Community-reported timelines vary considerably by compound and by the specific burnout symptoms being addressed. People using Semax and Selank for cognitive and anxiety symptoms often report noticing something within the first one to two weeks, though these reports are anecdotal rather than measured in a clinical setting. Compounds targeting energy metabolism, like MOTS-c and NAD+, tend to be described as working on a longer arc, with community reports placing meaningful changes at several weeks of consistent use. No clinical trial data establishes a verified timeline for any of these compounds in burnout.

Can these peptides be stacked, or is it safer to start with one?

Combining compounds, commonly called stacking, is standard practice in community protocols. The Semax and Selank pairing is probably the most discussed, targeting cognitive and anxiety symptoms simultaneously. NAD+ and MOTS-c are often combined in energy-focused protocols. More complex stacks involving BPC-157 and other compounds are also common in community use. That said, the safety data on combinations is even thinner than the data on individual compounds, and doing so with physician oversight is meaningfully safer than self-directing a complex stack from scratch.

Is burnout a recognized medical diagnosis?

The World Health Organization recognizes burnout as an occupational phenomenon and includes it in its International Classification of Diseases, but it is not classified as a medical condition in the way a disease or disorder would be. This matters practically: there is no FDA-recognized burnout diagnosis to drive formal drug development or clinical trials for burnout-specific treatments. The peptide research that exists for burnout-adjacent symptoms, including cognitive impairment, fatigue, HPA axis dysregulation, and inflammatory burden, comes from adjacent conditions rather than burnout itself, which explains why the evidence base looks the way it does across this list.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for burnout in one place.